Table 1:
Sociodemographic and Clinical Characteristics of Study Population
| Variables | HIV mono-infected n=60 (59.4%) |
HIV and HCV Co-infected n=19 (18.8%) |
HIV and HCV Negative n=22 (21.8%) |
P value |
|---|---|---|---|---|
| Sociodemographic factors | ||||
| Sex at Birth, n(%) | ||||
| Female | 28 (46.7%) | 7 (38.9%) | 13 (61.9%) | 0.323* |
|
Age at enrollment (years) Mean±SD |
51.53±9.31 | 53.22±6.04 | 53.14±5.00 | 0.612# |
| Race, n (%) | ||||
| Black/African American | 49 (83.1%) | 16 (88.9%) | 12 (57.1%) | 0.035 ** |
| White | 10(16.9%) | 2 (11.1%) | 9 (42.9%) | |
| Education (n (%)) | ||||
| High School Education or Less | 48 (80.0%) | 17 (94.4%) | 8 (38.1%) | <0.001 * |
| Post High School Education | 12 (20.0%) | 1 (5.6%) | 13 (61.9) | |
| Income, n (%) | ||||
| < $25,000 | 40 (66.7%) | 16 (88.9%) | 3 (14.3%) | <0.001 * |
| Behavioral Indicators, n(%) | ||||
| Cigarette smoker | ||||
| Current | 24 (40.0%) | 11 (61.1%) | 5 (23.8%) | 0.060* |
| Past | 29 (53.7%) | 13 (81.3%) | 6 (33.3%) | 0.019 * |
| Alcohol use | ||||
| Current | 32 (53.3%) | 4 (22.2%) | 18 (85.7%) | <0.001 * |
| Past | 45 (84.9%) | 14(82.4%) | 9 (60.0%) | 0.125** |
| Illicit use | ||||
| Current | 3 (5.0%) | 1 (5.6%) | 0(0%) | - |
| Past | 17 (28.3%) | 17 (94.4%) | 1 (4.8%) | <0.001 * |
| Clinical Indicators | ||||
| Duration of HIV Diagnosis, years, Mean±SD | 17.95±9.31 | 16.78±6.29 | - | 0.619€ |
| ART Duration, years, Median (Q1, Q3) | 5.50 (2.00,7.75) | 7.00 (2.00,7.75) | - | 0.478€€ |
| CD4 cell count/mm3, Median (Q1, Q3) | 692.00 (543.00,1030.00) | 642.00 (440.25,869.00) | - | 0.279€€ |
| Hepatitis B infected, n (%) | 5 (8.3%) | 2 (11.8%) | 0 (0%) | 0.286** |
| Hepatitis B and C infected, n (%) |
0 (0%) | 2 (11.8%) | 0 (0%) | - |
| Family History CVD, n(%) | 19 (31.7%) | 5 (27.8%) | 11 (52.4%) | 0.176* |
| Baseline ASCVD Risk Score, Median (Q1, Q3) | 0.05(0.02,0.09) | 0.06(0.03,0.09) | 0.05(0.03,0.12) | 0.804¥ |
| BMI, Mean±SD |
27.26±6.10 | 28.91±4.23 | 33.43±9.59 | 0.027 ## |
| Antihypertensive use, n(%) | 22 (95.7%) | 4 (100%) | 11(100%) | - |
| Statin use, n (%) | 8 (13.3 %) | 0 (0%) | 7 (33.3 %) | 0.013 ** |
| Other lipid-lowering medication use, n (%) |
9 (18.0%) | 0 (0%) | 6 (33.3%) | 0.029 ** |
| Systolic blood pressure mm Hg, Mean±SD | 124.63±16.90 | 130.06±19.03 | 128.43±20.26 | 0.457# |
| Total Cholesterol, mg/dL, Median (Q1, Q3) | 183.00 (151.00,202.25) | 161.00 (140.00,181.75) | 177.00 (152.50,205.00) | 0.108¥ |
| HDL, mg/dL, Median (Q1, Q3) | 51.00 (46.00,66.75) | 50.00 (43.75,69.50) | 49.00 (42.50,75.00) | 0.811¥ |
| LDL, mg/dL, Median (Q1, Q3) |
101.50 (76.00, 122.00) |
82.50 (65.25,101.50) | 104.00 (76.00,125.50) | 0.085¥ |
| Triglycerides, mg/dL, Median (Q1, Q3) |
94.50 (69.50,132.00) | 104.00 (76.75,126.50) | 72.00 (60.50,99.00) | 0.195¥ |
ART-antiretroviral therapy; ASCVD- atherosclerotic cardiovascular disease; BMI- body mass index;
CVD- cardiovascular disease; HDL-high density lipoprotein; HCV- hepatitis C virus; HIV- human immunodeficiency virus; LDL-low density lipoprotein
*
P value using Chi Square test.
**
P value using Fisher’s Exact test.
#
p value using One-Way ANOVA.
##
P value using Welch.
¥
P value using Kruskal Walli’s test.
€
P value using Independent t test.
€€
P value using Mann Whitney U test.